Gliclazide

PRODUCT NAME ：Gliclazide

C₁₅H₂₁N₃O₃S 323.41

SPECIFICATION：CP2020, BP2019, EP10, JP17

FUNCTION： For the treatment of NIDDM in conjunction with diet and exercise.

PACKAGE：25 kg/drum

Properties

Gliclazide is the second generation of sulfonylurea oral hypoglycemic agents. It has both the hypoglycemic effect and the improvement of coagulation function. It can not only improve the metabolism of diabetic patients, but also improve or delay the occurrence of diabetic vascular complications. Developed by SERVIER, France, it was first listed in France in 1972. It is marketed as dacicam, methanesulfide, methanesulfide, bicyclic urea, Lai Keyi, methanesulfide and Glick NAC. It is mainly used for mild and medium II diabetes without onset of ketosis. It can also improve the fundus lesion and metabolism of diabetic patients. Vascular dysfunction. It can be combined with oral hypoglycemic agents of double guanidin and insulin in the treatment of insulin-dependent diabetes mellitus, which can reduce the dosage of insulin. It began to supply to China market in 1980s and has been registered and sold in more than 130 countries around the world.

CAS No.

21187-98-4

Formula

C15H21N3O3S

Molecular Mass

323.41100

Exact Mass

323.13000

PSA

86.89000

Logp

3.43030